News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Analyst upgrades FormFactor to Strong Buy, citing AI test measurement demand and $140M Texas expansion.
  • Upgrade sets entry at $110, stop $98 and a 180-day target of $160, implying significant upside.
  • FormFactor's transformation into AI and silicon photonics testing supplier highlights investor interest in chip infrastructure plays.
  • Dyne Therapeutics priced an upsized $375M stock offering at $20.50 to fund neuromuscular drug programs.
  • The Dyne deal will add 18.3 million new shares, likely increasing near-term dilution for existing holders.
  • Combined themes of AI-capex upgrades and sizable biotech fundraising point to ongoing appetite for growth equities.

Latest Articles

NN, Inc. Expands Contract Manufacturing of Weapons Components, Secures New Awards with Leading Firearms Provider

NN, Inc. Expands Contract Manufacturing of Weapons Components, Secures New Awards with Leading Firearms Provider

NN, Inc. has successfully entered the US Tier 1 contract manufacturing market for firearm components, securing a multi-million dollar contract with a leading firearms provider. This new venture, part of NN's Defense & Electronics growth strategy, is expected to generate $12-15 million in sales starting Q3 2026 and ramp through 2028. The company's e…

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

Iridex Corporation announced the addition of its EndoProbe® Handpieces to the EyeProGPO product offering, making these disposable laser delivery devices available at preferred pricing to more than 4,300 EyeProGPO members. This expansion strengthens Iridex's collaboration with EyeProGPO and enhances ophthalmology practices' access to innovative reti…

AIHS and CECC Form Joint Venture to Develop, Invest In, Construct and Operate AI Data Centers in the United States

AIHS and CECC Form Joint Venture to Develop, Invest In, Construct and Operate AI Data Centers in the United States

Senmiao Technology Limited (Nasdaq: AIHS) announced a joint venture with Constant Energy Construction Corp. to develop, invest in, construct, and operate AI data centers across the United States. This strategic move marks AIHS's expansion into the digital infrastructure sector, leveraging CECC's energy infrastructure and construction expertise alon…

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Kamada Ltd. announced a three-year $50 million sales agreement to supply normal source plasma from its FDA-approved collection centers in Texas to a leading biopharmaceutical company specializing in plasma-derived therapies. The agreement validates Kamada's investment in U.S.-based plasma centers and supports its vertical integration and multi-year…

Helport AI Completes Key Consumer Finance AI Labor Workflow, Advancing Toward Scalable Replication

Helport AI Completes Key Consumer Finance AI Labor Workflow, Advancing Toward Scalable Replication

Helport AI Limited announced a major advancement in its AI Labor platform with successful deployment and validation of customer acquisition workflows across multiple consumer lending products in Mexico. The company demonstrated its AI system's capability to perform complex customer acquisition tasks traditionally done by human experts, achieving st…

GE Aerospace Partners with NASA, BETA Technologies, and Boeing on World’s First High-Altitude Hybrid Electric Flight

GE Aerospace Partners with NASA, BETA Technologies, and Boeing on World’s First High-Altitude Hybrid Electric Flight

GE Aerospace announced a groundbreaking achievement in hybrid electric aviation by successfully conducting the world's first high-altitude hybrid electric flight above 30,000 feet. In collaboration with NASA, BETA Technologies, and Boeing, the flight demonstrated the operational viability and endurance of GE Aerospace's megawatt-class hybrid electr…

Parsons To Modernize New York’s Intelligent Transportation System

Parsons To Modernize New York’s Intelligent Transportation System

Parsons Corporation secured a $33 million contract from the New York State Department of Transportation to deploy its iNET® intelligent transportation software across all 11 districts statewide. This contract includes system design, software development, integration, testing, and ongoing operations and maintenance to enhance traffic management effi…

Buy AleAnna (ANNA): Play Italy’s Gas Rebound with a Disciplined Long

Buy AleAnna (ANNA): Play Italy’s Gas Rebound with a Disciplined Long

AleAnna operates low-carbon natural gas assets in Italy's Po Valley and just received a DeGolyer & MacNaughton report identifying ~520 Bcf net prospective resource plus a production concession for Gradizza. With a market cap near $230M, enterprise value of about $110M and positive cash flow, the stock offers asymmetric upside if European gas prices…

Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar

Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar

Immuron Limited announced that CEO Steven Lydeamore will present at the Kalkine Media Webinar, discussing the company's biopharmaceutical developments, including their oral polyclonal antibody treatments like Travelan® for travelers’ diarrhea, and ongoing research on therapies for Clostridioides difficile and IBS. The presentation highlights Immuro…

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

Greenwich LifeSciences provided clinical updates on their Phase III FLAMINGO-01 trial evaluating GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence. The study received Data Safety Monitoring Board approval to continue without modification, and regulatory agencies have endorsed planned protocol changes including increased study …

Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

Seer, Inc.'s Special Committee of independent directors thoroughly reviewed an unsolicited acquisition proposal from the company's CEO Omid Farokhzad, M.D. to acquire all Class A shares at $2.45 per share plus contingent value rights. The Committee unanimously rejected the proposal, determining it undervalues Seer and does not fully recognize the c…

C3.ai: A Contrarian Long on Execution, Not Hype

C3.ai: A Contrarian Long on Execution, Not Hype

C3.ai (AI) has been punished after steep revenue contraction and a management shuffle, but the company is now smaller, cheaper on enterprise-value terms, and guided to positive progress in fiscal 2027. This trade idea outlines a long entry at $8.82 with a $15 target and $6.50 stop, arguing the risk/reward is attractive if management executes on boo…

Webuy Expands China Inbound Travel Capabilities Through Strategic Partnership with Moyu Travel and MeetPanda

Webuy Expands China Inbound Travel Capabilities Through Strategic Partnership with Moyu Travel and MeetPanda

Webuy Global Ltd, a Nasdaq-listed travel solutions company, announced a Memorandum of Understanding with Shanghai MoYu Travel Service and its MeetPanda platform to co-develop new, localized travel experiences targeting international visitors to China. This move follows strong growth in Webuy's China-focused platform, WeTrip, which saw transaction v…

Gold.com: The Re-Rating Story Has Begun

Gold.com: The Re-Rating Story Has Begun

Gold.com (GOLD) is a cash-generative, dividend-paying precious-metals platform trading at an undemanding multiple. Recent technical weakness has created an actionable entry near $38.34; we view a mid-term re-rating toward $48 as likely if metal markets remain constructive and execution stays steady. Trade plan included.